Efficacy, safety and feasibility of fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in pediatric patients receiving moderately and highly emetogenic chemotherapy – results of a non-interventional observation study

Efficacy, safety and feasibility of fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in pediatric patients receiving moderately and highly emetogenic chemotherapy – results of a non-interventional observation study

Abstract Background Chemotherapy-induced nausea and vomiting (CINV) belong among the most burdensome side effects in hemato-oncology. Mostly, a combination of ondansetron and dexamethasone is used as antiemetic prophylaxis in pediatric patients undergoing emetogenic chemotherapy. However, dexamethas...

Full description

Bibliographic Details
Main Authors: Semjon Willier, Karin Melanie Cabanillas Stanchi, Martina von Have, Vera Binder, Franziska Blaeschke, Judith Feucht, Tobias Feuchtinger, Michaela Döring
Format: Article
Language:English
Published: BMC 2019-11-01
Series:BMC Cancer
Subjects:
Fosaprepitant
Aprepitant
Pediatric patients
Emetogenic chemotherapy
Chemotherapy-induced nausea and vomiting
Ondansetron
Online Access:http://link.springer.com/article/10.1186/s12885-019-6252-6

Internet

http://link.springer.com/article/10.1186/s12885-019-6252-6

Similar Items